Regulatory Affairs Outsourcing
Europe · 1 shared keyword
Updated
Reviewed by Chandani Patel
Europe Bioanalytical Testing Services Market Industry Trends and Forecast to 2034: Segmented by (Test, Molecule, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.22 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $942.1 Mn | — | — |
| 2025 (base) | $1.03 Bn | +$85.7 Mn | — |
| 2026 (forecast) | $1.12 Bn | +$93.5 Mn | +9.1% |
| 2027 (forecast) | $1.22 Bn | +$102.0 Mn | +19% |
| 2028 (forecast) | $1.33 Bn | +$111.3 Mn | +29.9% |
| 2029 (forecast) | $1.46 Bn | +$121.5 Mn | +41.7% |
| 2030 (forecast) | $1.59 Bn | +$132.5 Mn | +54.6% |
| 2031 (forecast) | $1.73 Bn | +$144.6 Mn | +68.6% |
| 2032 (forecast) | $1.89 Bn | +$157.7 Mn | +84% |
| 2033 (forecast) | $2.06 Bn | +$172.1 Mn | +100.7% |
| 2034 (forecast) | $2.25 Bn | +$187.7 Mn | +119% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $1.03 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.25 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, molecule and end user (see all) |
| Key players | Labcorp, Charles River Laboratories, ICON Plc, Eurofins Scientific, Frontage Laboratories (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Bioanalytical testing services measure drugs and biomarkers in samples from studies to show how medicines behave in the body.
Key segments of the bioanalytical Testing Services market include test (Pharmacokinetics, Immunogenicity and Biomarkers) and molecule (Small Molecules, Biologics and Cell and Gene Therapies).
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the bioanalytical Testing Services market. Many companies now outsource work they used to do in-house.
Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the bioanalytical Testing Services market room to grow.
Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the bioanalytical Testing Services market.
The bioanalytical Testing Services market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[1]
[1] European Commission, health technology assessment. Checked 14 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how bioanalytical Testing Services services are delivered and paid for in Europe. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Bioanalytical Testing Services right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 1 shared keyword
Europe
Europe
Europe
Europe
Europe
Digital Health · Europe
Pharmaceuticals · Europe
Digital Health · Europe
Digital Health · Europe
Pharmaceuticals · Europe
Pharmaceuticals · Europe